IRADIMED (IRMD) heads into its Q1 2026 update after a solid run of results, with Q4 2025 revenue at US$22.7 million and basic EPS of US$0.51 helping lift trailing twelve month revenue to US$83.8 million and EPS to US$1.77. Over the past six reported quarters, revenue has moved from US$18.3 million in Q3 2024 to US$22.7 million in Q4 2025. Quarterly EPS has ranged from US$0.37 to US$0.51 as earnings tracked that top line expansion. With a trailing net profit margin of 26.8% and five year earnings compounding at about 26.5% a year, the current release comes against a backdrop of consistent profitability and firm margins.

See our full analysis for IRADIMED.

With the headline numbers set, the next step is to see how this earnings profile lines up with the dominant narratives around IRADIMED, and to highlight which stories are backed by the data and which ones face a tougher test.

11.5% Revenue Growth Track Supported by Backlog Story

• Trailing twelve month revenue of US$83.8 million sits alongside revenue forecasts of roughly 11.5% annual growth, slightly ahead of the cited US market expectation of 11% a year.
• Analysts' consensus view that higher MRI procedure volumes and the new 3870 pump can support multiyear growth is put to the test by these figures, as:
  • Forecast revenue growth at about 11.5% a year is slower than the 13.1% annual pace some analysts assume in the narrative, so investors can check how much of that gap the backlog and new product uptake might close.
  • The expectation that the 3870 pump commands roughly 12% higher average selling prices sits against the current 26.8% net margin, giving readers a concrete margin baseline to compare with any future uplift from that pricing power.

26.8% Net Margin and 16.9% EPS Growth Underpin the Bull Case

• Trailing net profit margin of 26.8% and trailing earnings growth of 16.9% over the past year line up with a five year earnings compound rate of about 26.5% a year, pointing to a business that has produced consistent profitability in the recent period covered by the data.
• Bullish arguments that operational investments and pricing strength can support higher margins are being measured against these numbers, because:
  • Analysts in the narrative expect profit margins to reach 28.1% in about three years, only modestly above the current 26.8%, which suggests the bullish case leans more on sustained earnings growth than on a big jump in profitability from here.
  • Forecast earnings growth of around 14.2% a year is lower than the roughly 26.5% five year earnings compound rate, so readers can see that the bullish story is based on durability of growth at a slower pace rather than a repeat of the past compounding stretch.

On these numbers, bulls are effectively arguing that today’s 26.8% margin and 16.9% earnings growth are just the starting point for a longer runway, not the peak, which is why a closer look at their full case can be helpful for context. 🐂 IRADIMED Bull Case

P/E Of 49.6x Versus DCF Fair Value Of US$58.65 Fuels Bear Concerns

• The shares trade on a trailing P/E of 49.6x compared with 23.8x for the broader US Medical Equipment industry and a DCF fair value of US$58.65 against a current share price of US$87.15, highlighting a valuation gap in the supplied data.
• Bears argue that reliance on a narrow MRI pump and monitor range amplifies that valuation risk, and the data helps frame why, as:
  • Expected earnings growth of about 14.2% a year sits below the 15.8% forecast for the US market and below the roughly 26.5% five year earnings compound rate, so the current 49.6x P/E is not paired with the fastest growth profile in the dataset.
  • The DCF fair value of US$58.65 is well below both the US$87.15 share price and the US$118.67 analyst price target, which means any disappointment around product concentration or execution on the 3870 pump rollout could matter more when the valuation already assumes strong performance.

For readers who worry the current 49.6x P/E leaves little room for missteps, it can be useful to walk through how skeptics build their case off these same earnings and valuation figures. 🐻 IRADIMED Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for IRADIMED on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Curious whether the optimism in this update really holds up for you personally? Take a closer look at the full picture and pressure test the positives that are catching attention, starting with 3 key rewards.

See What Else Is Out There

The current 49.6x P/E and valuation gap versus the DCF fair value of US$58.65 highlight how much expectations already embedded in IRADIMED's price can amplify disappointment risk.

If that kind of rich pricing makes you uneasy, compare this setup with companies that pair lower expectations with stronger value signals by checking out 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.